Brett Leav
Overview
Explore the profile of Brett Leav including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
8926
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrett N, Reddy T, Yende-Zuma N, Takalani A, Woeber K, Bodenstein A, et al.
PLOS Glob Public Health
. 2024 Dec;
4(12):e0003260.
PMID: 39636838
Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after...
2.
Fisher L, Kee J, Liu A, Espinosa C, Randhawa A, Ludwig J, et al.
JAMA Netw Open
. 2024 May;
7(5):e2412835.
PMID: 38780941
Importance: SARS-CoV-2 viral load (VL) in the nasopharynx is difficult to quantify and standardize across settings, but it may inform transmission potential and disease severity. Objective: To characterize VL at...
3.
Sherman A, Tuan J, Cantos V, Adeyiga O, Mahoney S, Ortega-Villa A, et al.
Clin Infect Dis
. 2024 Apr;
79(2):364-374.
PMID: 38598658
Background: Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE)...
4.
Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, et al.
Hum Vaccin Immunother
. 2024 Mar;
20(1):2327736.
PMID: 38513689
The objective of the study was to assess the safety and immunogenicity of mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This...
5.
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
Dukes C, Potez M, Lancet J, Kuter B, Whiting J, Mo Q, et al.
Vaccines (Basel)
. 2024 Jan;
12(1).
PMID: 38250826
Cancer patients are at an increased risk of morbidity and mortality from SARS-CoV-2 infection and have a decreased immune response to vaccination. We conducted a study measuring both the neutralizing...
6.
Hejazi N, Shen X, Carpp L, Benkeser D, Follmann D, Janes H, et al.
Int J Infect Dis
. 2023 Oct;
137:28-39.
PMID: 37820782
Background: Stochastic interventional vaccine efficacy (SVE) analysis is a new approach to correlate of protection (CoP) analysis of a phase III trial that estimates how vaccine efficacy (VE) would change...
7.
Rick A, Laurens M, Huang Y, Yu C, Martin T, Rodriguez C, et al.
EBioMedicine
. 2023 Sep;
96:104799.
PMID: 37738833
Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual...
8.
Theodore D, Branche A, Zhang L, Graciaa D, Choudhary M, Hatlen T, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2323349.
PMID: 37440227
Importance: Current data identifying COVID-19 risk factors lack standardized outcomes and insufficiently control for confounders. Objective: To identify risk factors associated with COVID-19, severe COVID-19, and SARS-CoV-2 infection. Design, Setting,...
9.
Narayanasamy S, Curtis L, Hernandez A, Woods C, Moody M, Sulkowski M, et al.
Clin Infect Dis
. 2023 Jul;
77(12):1635-1643.
PMID: 37435958
While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches...
10.
Turley C, Tables L, Fuller T, Sanders L, Scott H, Moodley A, et al.
Vaccine
. 2023 Jun;
41(33):4899-4906.
PMID: 37385888
Questions remain regarding the effect of baseline host and exposure factors on vaccine efficacy (VE) across pathogens and vaccine platforms. We report placebo-controlled data from four Phase 3 COVID-19 trials...